Literature DB >> 22549897

Cardiovascular disease and cognitive dysfunction in systemic lupus erythematosus.

Sara G Murray1, Jinoos Yazdany, Rachel Kaiser, Lindsey A Criswell, Laura Trupin, Edward H Yelin, Patricia P Katz, Laura J Julian.   

Abstract

OBJECTIVE: Cognitive dysfunction and cardiovascular disease are common and debilitating manifestations of systemic lupus erythematosus (SLE). In this study, we evaluated the relationship between cardiovascular events, traditional cardiovascular risk factors, and SLE-specific risk factors as predictors of cognitive dysfunction in a large cohort of participants with SLE.
METHODS: Subjects included 694 participants from the Lupus Outcomes Study (LOS), a longitudinal study of SLE outcomes based on an annual telephone survey querying demographic and clinical variables. The Hopkins Verbal Learning Test-Revised and the Controlled Oral Word Association Test were administered to assess cognitive function. Multiple logistic regression was used to identify cardiovascular events (myocardial infarction, stroke), traditional cardiovascular risk factors (hypertension, hyperlipidemia, diabetes mellitus, obesity, smoking), and SLE-specific risk factors (antiphospholipid antibodies [aPL], disease activity, disease duration) associated with cognitive impairment in year 7 of the LOS.
RESULTS: The prevalence of cognitive impairment as measured by verbal memory and verbal fluency metrics was 15%. In adjusted multiple logistic regression analyses, aPL (odds ratio [OR] 2.10, 95% confidence interval [95% CI] 1.3-3.41), hypertension (OR 2.06, 95% CI 1.19-3.56), and a history of stroke (OR 2.27, 95% CI 1.16-4.43) were significantly associated with cognitive dysfunction. In additional analyses evaluating the association between these predictors and severity of cognitive impairment, stroke was significantly more prevalent in participants with severe impairment when compared to those with mild or moderate impairment (P = 0.036).
CONCLUSION: These results suggest that the presence of aPL, hypertension, and stroke are key variables associated with cognitive impairment, which may aid in identification of patients at greatest risk.
Copyright © 2012 by the American College of Rheumatology.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22549897      PMCID: PMC3705733          DOI: 10.1002/acr.21691

Source DB:  PubMed          Journal:  Arthritis Care Res (Hoboken)        ISSN: 2151-464X            Impact factor:   4.794


  35 in total

1.  "Subcortical" cognitive impairment in patients with systemic lupus erythematosus.

Authors:  E Leritz; J Brandt; M Minor; F Reis-Jensen; M Petri
Journal:  J Int Neuropsychol Soc       Date:  2000-11       Impact factor: 2.892

2.  Validity of brief screening tools for cognitive impairment in rheumatoid arthritis and systemic lupus erythematosus.

Authors:  Laura J Julian; Jinoos Yazdany; Laura Trupin; Lindsey A Criswell; Edward Yelin; Patricia P Katz
Journal:  Arthritis Care Res (Hoboken)       Date:  2012-03       Impact factor: 4.794

3.  Validity of self-reported hypertension in the National Health and Nutrition Examination Survey III, 1988-1991.

Authors:  C M Vargas; V L Burt; R F Gillum; E R Pamuk
Journal:  Prev Med       Date:  1997 Sep-Oct       Impact factor: 4.018

4.  Cognitive impairment in patients with systemic lupus erythematosus.

Authors:  J G Hanly; J D Fisk; G Sherwood; E Jones; J V Jones; B Eastwood
Journal:  J Rheumatol       Date:  1992-04       Impact factor: 4.666

5.  Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus.

Authors:  M C Hochberg
Journal:  Arthritis Rheum       Date:  1997-09

6.  Effects of age and hypertension status on cognition: the Veterans Affairs Normative Aging Study.

Authors:  Christopher B Brady; Avron Spiro; J Michael Gaziano
Journal:  Neuropsychology       Date:  2005-11       Impact factor: 3.295

7.  Validation of a Systemic Lupus Activity Questionnaire (SLAQ) for population studies.

Authors:  E W Karlson; L H Daltroy; C Rivest; R Ramsey-Goldman; E A Wright; A J Partridge; M H Liang; P R Fortin
Journal:  Lupus       Date:  2003       Impact factor: 2.911

8.  Cognitive dysfunction in systemic lupus erythematosus: prevalence and correlates.

Authors:  J Olazarán; J López-Longo; I Cruz; A Bittini; L Carreño
Journal:  Eur Neurol       Date:  2009-04-30       Impact factor: 1.710

9.  Cognitive impairment: an increasingly important complication of type 2 diabetes: the age, gene/environment susceptibility--Reykjavik study.

Authors:  Jane S Saczynski; María K Jónsdóttir; Melissa E Garcia; Palmi V Jonsson; Rita Peila; Gudny Eiriksdottir; Elin Olafsdottir; Tamara B Harris; Vilmundur Gudnason; Lenore J Launer
Journal:  Am J Epidemiol       Date:  2008-10-03       Impact factor: 4.897

10.  Systemic lupus erythematosus and the risk of cardiovascular disease: results from the nurses' health study.

Authors:  A Elisabeth Hak; Elizabeth W Karlson; Diane Feskanich; Meir J Stampfer; Karen H Costenbader
Journal:  Arthritis Rheum       Date:  2009-10-15
View more
  11 in total

1.  Anti-NR2 antibodies, blood-brain barrier, and cognitive dysfunction.

Authors:  Gaurav Gulati; Philip H Iffland; Damir Janigro; Bin Zhang; Michael E Luggen
Journal:  Clin Rheumatol       Date:  2016-06-29       Impact factor: 2.980

Review 2.  The clinical significance of antiphospholipid antibodies in systemic lupus erythematosus.

Authors:  Ozan Ünlü; Stephane Zuily; Doruk Erkan
Journal:  Eur J Rheumatol       Date:  2015-12-29

3.  Anti-GAPDH Autoantibody Is Associated with Increased Disease Activity and Intracranial Pressure in Systemic Lupus Erythematosus.

Authors:  Jingjing Sun; Xue Li; Haotian Zhou; Xiaoyun Liu; Jingjing Jia; Qizhi Xie; Sijia Peng; Xiaolin Sun; Qingwen Wang; Li Yi
Journal:  J Immunol Res       Date:  2019-03-31       Impact factor: 4.818

4.  Non-criteria anti-phospholipid antibodies and cognitive impairment in SLE.

Authors:  Michael E Luggen; Gaurav Gulati; Bin Zhang; Rohan A Willis; Emilio B Gonzalez
Journal:  Clin Rheumatol       Date:  2015-11-12       Impact factor: 2.980

Review 5.  Neuropsychiatric systemic lupus erythematosus: pathogenesis and biomarkers.

Authors:  Hélène Jeltsch-David; Sylviane Muller
Journal:  Nat Rev Neurol       Date:  2014-09-09       Impact factor: 42.937

Review 6.  Cardiovascular disease in lupus: insights and updates.

Authors:  Jason S Knight; Mariana J Kaplan
Journal:  Curr Opin Rheumatol       Date:  2013-09       Impact factor: 5.006

Review 7.  Multimorbidity in rheumatic conditions.

Authors:  Helga Radner
Journal:  Wien Klin Wochenschr       Date:  2016-10-13       Impact factor: 1.704

8.  The association between systemic lupus erythematosus and dementia A meta-analysis.

Authors:  Zhuoxian Zhao; Natalia P Rocha; Haitham Salem; Breno S Diniz; Antonio L Teixeira
Journal:  Dement Neuropsychol       Date:  2018 Apr-Jun

9.  Efficacy of Acceptance and Commitment Therapy in Reducing Disappointment, Psychological Distress, and Psychasthenia among Systemic Lupus Erythematosus (SLE) Patients.

Authors:  Maryam Sahebari; Mohammad Javad Asghari Ebrahimabad; Ali Ahmadi Shoraketokanlo; Hamidreza Aghamohammadian Sharbaf; Mandana Khodashahi
Journal:  Iran J Psychiatry       Date:  2019-04

10.  Disease activity, autoantibodies, and inflammatory molecules in serum and cerebrospinal fluid of patients with Systemic Lupus Erythematosus and Cognitive Dysfunction.

Authors:  Alí Duarte-García; Juanita Romero-Díaz; Sandra Juárez; Alba Cicero-Casarrubias; Hilda Fragoso-Loyo; Carlos Núñez-Alvarez; Luis Llorente; Jorge Sánchez-Guerrero
Journal:  PLoS One       Date:  2018-05-03       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.